0
Deep & Emerging Tech·October 23, 2026·1 min read

Xona Raises $250 Million to Remake 50-Year-Old GPS

Share

A $250M round at a $2.45B valuation to rebuild GPS with a commercial satellite network shows navigation is being treated as strategic infrastructure, not a free public good. Any product that depends on precise, reliable positioning—AVs, drones, logistics—should be tracking alternative PNT providers as potential resilience and performance levers.

Deep & Emerging Tech

The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.

For oncology operators, the question isn’t just whether Moderna’s cancer vaccine can match Keytruda in the short term—it’s whether it can durably suppress recurrence over years, which changes trial design, follow-up infrastructure, and payer negotiations. Early data will drive headlines, but long-term outcomes will drive formulary and care-pathway rewrites.